What's going on with the Incannex (ASX:IHL) share price today?

The company's shares had a horror start today before regaining lost ground.

| More on:
A woman puts up her hands and looks confused while sitting at her computer.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Incannex shares fell to a low of 60 cents this morning before rebounding
  • The company will issue loyalty options to eligible shareholders at an exercise price of 35 cents each
  • In addition, a second piggy-back option will also be available, exercisable at $1 per option

The Incannex Healthcare Ltd (ASX: IHL) share price is wobbling today following a company announcement regarding loyalty options.

In the first hour of morning trade, the medicinal cannabis company's shares were trading as low as 60 cents — a fall of almost 10%.

They then bounced back into the green at 68 cents before falling into the red again. At the time of writing, they are swapping hands for 65.5 cents, down 1.5% on yesterday's closing price.

Incannex set to issue loyalty options

A possible catalyst for the movement in the Incannex share price could be the fear of an impending share dilution.

According to its release, Incannex intends to undertake a loyalty issue of options to all eligible shareholders.

The options will be distributed for nil consideration at a ratio of one free loyalty option for every 15 shares held.

The loyalty options will have an exercise price of 35 cents each. Shareholders will have until Friday, April 22 to take up the offer. If exercised, each loyalty option will result in the allotment and issue of one fully paid ordinary Incannex share.

Furthermore, each loyalty option exercised will also result in the issue of a second 'piggy-back option'.

This will be issued for nil consideration at a ratio of one for every two loyalty options exercised by the expiry date.

The piggy-back options will have an exercise price of $1.00, expiring 28 April, 2023.

Incannex highlighted the loyalty option and piggy-back options are intended to "reward loyal shareholders who have supported Incannex". This particularity relates to the recent clinical trial success with IHL-42X for obstructive sleep apnoea.

Investors will have until 23 March (record date) to buy the company's shares to be involved with the latest offer.

Incannex CEO and managing director Joel Latham commented:

Incannex has a remarkable base of shareholders who understand our company, our clinical programs and high ambitions.

The loyalty option is intended to reward our loyal shareholders whilst simultaneously assisting Incannex with the funding requirement for the next phase of development.

Our research is highly focused on completing the clinical trials necessary to commercialise our sophisticated cannabinoid and psychedelic medicines developed for prescription, or administration, by health professionals.

Incannex share price snapshot

Over the past 12 months, the Incannex share price has surged close to 230%, while it is up 8% this year to date.

The company's shares reached a multi-year high of 75.5 cents earlier this month, before moving in circles.

On valuation grounds, Incannex has a market capitalisation of around $804.9 million.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

stockmarket graphic in background with man looking at stockmarket on phone
Healthcare Shares

CSL shares are a buy – UBS

This expert is optimistic on what the business can achieve despite headwinds.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Broker says this ASX 200 biotech stock is a top buy

Let's see what Bell Potter is saying about this biotech.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why CSL shares are a buy today despite the looming Trump tariffs

A leading expert believes CSL shares are still trading for a bargain today. Here's why.

Read more »

A businesswoman pulls her glasses down in shock to look at the bad news on her computer.
Healthcare Shares

Why did the Telix share price just crash 16%?

Investors are sending the Telix share price plunging today. But why?

Read more »

Broker analysing the share price.
Healthcare Shares

Expert: 2 ASX healthcare stocks to avoid before reporting season

Not all healthcare stocks are created equal.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Should I buy Pro Medicus or CSL shares ahead of earnings season?

The ASX healthcare sector may be currently undervalued.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why Mesoblast shares can keep storming higher

More big returns could be on the way for buyers of this high risk stock according to Bell Potter.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »